Under construction – not a live service
Sign in
Taking peopleNo phase

Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease

Key facts

Who runs it
University Hospital, Lille
Where
France9 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
447 people, planned
Started
23 Oct 2019
Expected to end
Apr 2027
Type of study
Observational, 3 groups
Record updated
19 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • For SAH group:
  • Alcohol consumption :; On average> 40 g / day for women and 50 g / day for men; Duration:> 5 years
  • Recent jaundice episode (less than 3 months)
  • Bilirubin> 50 mg / l (85μmol / l); For NSAH group:
  • Alcohol consumption :
  • On average> 40 g / day for women and 50 g / day for men
  • Duration:> 5 years; For cirrhosis (control) group:
  • Alcohol consumption :; On average> 40 g / day for women and 50 g / day for men; Duration:> 5 years
  • Unambiguous presence of cirrhosis criteria, including:; clinical signs (ascites, stellar angiomas ...) and / or; radiological signs (scanner or MRI: signs of hepatic dysmorphism and / or portal hypertension) and / or; biological signs (increased INR, thrombocytopenia) and / or; endoscopic signs (oesophageal / gastric varices)

Who cannot take part

  • Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)
  • HIV infection; For cirrhosis (control) group:
  • Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)
  • HIV infection
  • For NAH and NSAH groups:
  • Presence of hepatocellular carcinoma
  • History established / suggestive of HAA (Clinical, biological and / or histological criteria) in particular absence of jaundice episode
  • Presence of hepatocellular carcinoma

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Alcoholic hepatitis carries a risk of high mortality at short term, especially in its severe form. Its diagnosis is confirmed by liver biopsy. The prevalence of alcoholic hepatitis, severe or not severe, is poorly known and prospective data are needed. The present observational study aims to define the prevalence of alcoholic hepatitis among patients admitted for jaundice and determine their outcome according to the severity. Survival and markers of liver dysfunction will be assessed. A biobank including genetic samples will be created to identify the disease profile in terms of inflammation and regeneration. The performance of non-invasive criteria for diagnosis will also be studied.

The 3 groups in the trial

  • cirrhosis

    Patients with alcoholic liver disease without alcoholic hepatitis

  • severe alcoholic hepatitis

    Patients with severe alcoholic hepatitis ( Maddrey score ≥32)

  • non-severe alcoholic hepatitis

    Patients with non-severe alcoholic hepatitis (Maddrey score \<32)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
19 May 2026